Heart failure (HF) is a worldwide epidemic with treatments costing tens of billions of dollars every year. Despite this investment, HF therapies have limited efficacy in reducing disease progression. Recent insights in fundamental myocyte biology, HF etiologies and pathogenic mechanisms are propelling new strategies to treat and prevent HF. This meeting will explore biologic and technical advances that inform the genetic architecture, molecular pathogenesis and innovative approaches to treat HF. This comes at a time when very large human HF datasets are available and can be interrogated using advanced computational and bioinformatic approaches.